New drug combo shows promise for Hard-to-Treat GI cancers
NCT ID NCT03929666
First seen Jun 24, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This study tested a new drug called zanidatamab (ZW25) combined with standard chemotherapy in 74 people with advanced HER2-positive cancers of the stomach, bile duct, or colon. The goal was to see if the combination is safe and shrinks tumors. Results will help decide if larger studies are warranted.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Zanidatamab (ZW25) plus standard chemotherapy drugs
What this could lead to
If successful, this could point toward a more effective first-line treatment option for people with HER2-positive gastrointestinal cancers.
What could go wrong
This is a small, early-phase trial (Phase 2) with no control group, so results may not confirm real benefit. Side effects from combining multiple drugs could be significant.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Asan Medical Center
Seoul, 05505, South Korea
-
CECIM Biocinetic
Santiago, 8320000, Chile
-
Centro Internacional de Estudios Clínicos
Santiago, 8420383, Chile
-
Centro de Investigacion Clinica SAGA
Santiago, 7500653, Chile
-
Fox Chase Cancer Center
Philadelphia, Pennsylvania, 19111, United States
-
H. Lee Moffitt Cancer Center
Tampa, Florida, 33612, United States
-
Hoag Memorial Hospital Presbyterian
Newport Beach, California, 92663, United States
-
Icegclinic Research & Care
Santiago, 8241479, Chile
-
Korea University Anam Hospital
Seoul, 02841, South Korea
-
MD Anderson Cancer Center
Houston, Texas, 77030, United States
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
-
Nebraska Methodist Hospital
Omaha, Nebraska, 68114, United States
-
Princess Margaret Cancer Center
Toronto, Ontario, M5G 2C1, Canada
-
Pusan National University
Busan, 49241, South Korea
-
Sarah Cannon Research Institute
Nashville, Tennessee, 37203, United States
-
Seoul National University Bundang Hospital
Seongnam-si, Gyeonggi-do, 13620, South Korea
-
Seoul National University Hospital
Seoul, 03080, South Korea
-
Severance Hospital
Seoul, 03722, South Korea
-
The Cancer and Hematology Centers
Grand Rapids, Michigan, 49503, United States
-
The Ottawa Hospital Cancer Centre
Ottawa, Ontario, K1H 8L6, Canada
-
USC/Norris Comprehensive Cancer Center
Los Angeles, California, 90033, United States
-
University of Chicago
Chicago, Illinois, 60637, United States
-
Virginia Mason Medical Center
Seattle, Washington, 98101, United States